Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Actelion Pharmaceuticals Ltd
Actelion Pharmaceuticals Ltd_20100107

Actelion Pharmaceuticals Ltd patents


Recent patent applications related to Actelion Pharmaceuticals Ltd. Actelion Pharmaceuticals Ltd is listed as an Agent/Assignee. Note: Actelion Pharmaceuticals Ltd may have other listings under different names/spellings. We're not affiliated with Actelion Pharmaceuticals Ltd, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Actelion Pharmaceuticals Ltd-related inventors


Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist

The invention relates to a crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone hydrochloride, processes for the preparation thereof, pharmaceutical compositions containing said crystalline form, and its use as medicament, especially as orexin receptor antagonist.... Actelion Pharmaceuticals Ltd

Antibacterial benzothiazole derivatives

and salts thereof.... Actelion Pharmaceuticals Ltd

Pharmaceutical combination comprising a selective s1p1 receptor agonist

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]propylimino)-3-o-tolyl-thiazolidin-4-one or a pharmaceutically acceptable salt thereof and a second active ingredient which is selected from the group consisting of methyl fumarate, dimethyl fumarate, (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, and 2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)but-2-ene-1,4-dioate, or a pharmaceutically acceptable... Actelion Pharmaceuticals Ltd

Cxcr7 receptor modulators

wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and A1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7... Actelion Pharmaceuticals Ltd

Dosing regimen for a selective s1p1 receptor agonist

The present invention relates to a dosing regimen for (R)-5-[3-chloro-4-(2,3-dihydroxy-propoxy)-benz[Z]ylidene]-2-([Z]-propylimino)-3-o-tolyl-thiazolidin-4-one.... Actelion Pharmaceuticals Ltd

Antibacterial basic biaromatic derivatives with aminoalkoxy substitution

wherein R1a, R2a, R2b, R3a, R3b, R4, R5, Ul, U2, U3, U4, V1, V2, V3, V4, X and Q and n are as defined in the specification. It further relates pharmaceutical compositions containing these compounds and the uses of these compounds in the manufacture of medicaments for the treatment of... Actelion Pharmaceuticals Ltd

Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators

wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.... Actelion Pharmaceuticals Ltd

Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators

wherein R1 and R2 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.... Actelion Pharmaceuticals Ltd

8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives

The invention relates to compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators of the CXCR3 receptor.... Actelion Pharmaceuticals Ltd

Pyrazole compounds and their use as t-type calcium channel blockers

wherein X, Y, R1, R2, (R4)n, and (R5)m are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium T-channel blockers.... Actelion Pharmaceuticals Ltd

Antibacterial quinazoline-4(3h)-one derivatives

and salts thereof.... Actelion Pharmaceuticals Ltd

Antibacterial 1h-indazole and 1h-indole derivatives

wherein A is a bond, CH2CH2, CH═CH or C≡C; R1A is H or halogen; R2A is H, alkoxy or halogen; R3A is H, alkoxy, hydroxyalkoxy, alkoxyalkoxy, thioalkoxy, trifluoromethoxy, amino, hydroxyalkyl, 2-hydroxyacetamido, 1-aminocyclopropyl, 1-hydroxymethyl-cycloprop-1-yl, 1-((phosphonooxy)methyl)cyclopropyl, 1-(((dimethylglycyl)oxy)methyl)cyclopropyl, trans-2-hydroxymethyl-cycloprop-1-yl, 1,2-dihydroxyethyl, 3-hydroxyoxetan-3-yl, 3-(hydroxyalkyl)oxetan-3-yl, 3-aminooxetan-3-yl, 3-hydroxythietan-3-yl, morpholin-4-ylalkoxy, morpholin-4-yl-alkyl, oxazol-2-yl or [1,2,3]triazol-2-yl; and R1B is hydroxyalkyl,... Actelion Pharmaceuticals Ltd

Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators

wherein R1 and R2 are as described in the description, and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.... Actelion Pharmaceuticals Ltd

Use of benzimidazole-proline derivatives

The present invention relates to compounds of the formula (I), wherein Ar1 and Ar2 are as described in the description and to their use as pharmaceuticals for the treatment of sundown syndrome. The invention also relates to the preparation of such compounds and of pharmaceutically acceptable salts thereof.... Actelion Pharmaceuticals Ltd








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Actelion Pharmaceuticals Ltd in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Actelion Pharmaceuticals Ltd with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###